Phase I trial of single-ascending dose of MMI-0100 in volunteers in the Netherlands
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
Price : $35 *
At a glance
- Drugs MMI 0100 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Moerae Matrix
- 23 May 2018 Results assessing the safety, tolerability and PK profile of IH MMI-0100 in three Phase I trials (n=75) presented at the 114th International Conference of the American Thoracic Society
- 28 Jul 2015 Results published in a Moerae Matrix media release.
- 28 Jul 2015 Status changed from recruiting to completed according to a Moerae Matrix media release.